Cambridge-based startup Lucida Medical, a company dedicated to improving cancer diagnostics, will detect cancers using artificial intelligence, Med Tech reports.
While MRI is the imaging technique of choice for assessing a range of cancers, including prostate cancer, in the UK alone, the number of radiologists is predicted to reach 40% by 2027, indicating the need for a streamlined, simplified and accurate means of cancer diagnosis, Med Tech reports.
A clinical study shows that radiologists can miss 12% of significant prostate cancer cases using MRI. The data, presented at the European Society of Urogenital Radiology (ESUR) in September 2023, shows that Pi could help reduce undetected cancers by up to 6% while reducing avoidable biopsies by up to 43%.
According to Med Tech, with the help of artificial intelligence, Pi analyzes MRIs and is fully integrated into the radiologist’s workflow, targeting key issues related to variability, radiologist timing and diagnostic accuracy in prostate cancer. Specifically, Pi is designed to be used by radiologists to evaluate and report prostate MRI studies by automatically creating 3D segmentations, volumes and risk scores. Its results can be used to save radiologists time and to support biopsy and treatment decisions.
“We desperately need to cut waiting times, detect cancer early, and provide patients and clinicians with all the information needed to for optimum treatment. With this CE mark, the results of our investment in AI and clinical research over the last four years can now be used by doctors to provide the best possible diagnosis for men with suspected prostate cancer”, explained co-founder and chief medical officer Professor Evis Sala, chair of radiology at the Università Cattolica del Sacro Cuore and director of the Advanced Radiology Centre at the Policlinico Universitario A. Gemelli, IRCCS.
Lucida Medical will demonstrate Pi at the Radiological Society of North America (RSNA) 2023 Annual Meeting.
What is Pi?
Prostate Intelligence (Pi) is an AI and machine learning based software system designed to help radiologists detect and report the presence of prostate cancer lesions from MR scans (MRI).
